Category: Ocrevus

New Data for Genentech’s Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

  75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression…

Stuart Schlossman

Ocrelizumab Data Go Against Traditional Conceptions of Wearing Off Effect

 November 18, 2021  – Marco Meglio Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising…

Stuart Schlossman

Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021

 Ocrevus data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5…

Stuart Schlossman

1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML

 By Steve Bryson PhD on Oct 07, 2021 One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare…

Stuart Schlossman

B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS

  New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against…

Stuart Schlossman

MS Therapies That Deplete B-cells Appear to Work Against COVID Immunity

 MAY 14, 2021    BY STEVE BRYSON PHD       Click HERE to Subscribe for the MS Beacon eNewsletter! B-cell-depleting…

Stuart Schlossman

Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients

Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive of multiple sclerosis (MS),…

Stuart Schlossman

COVID-19 in ocrelizumab-treated people with multiple sclerosis

  Abstract Background: There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory…

Stuart Schlossman

Black MS Patients See More Rapid B-Cell Repopulation

  May have implications for timing of lab draws and anti-CD20 dosing, researchers say by Ed Susman, Contributing Writer, MedPage Today April 20, 2021…

Stuart Schlossman

New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

April 16, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no…

Stuart Schlossman

Categories

Latest Blog Posts